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Abstract
As an obligatory pathogen, influenza virus co-opts host cell machinery to harbor infection and to produce progeny viruses.
In order to characterize the virus-host cell interactions, several genome-wide siRNA screens and proteomic analyses have
been performed recently to identify host factors involved in influenza virus infection. CD81 has emerged as one of the top
candidates in two siRNA screens and one proteomic study. The exact role played by CD81 in influenza infection, however,
has not been elucidated thus far. In this work, we examined the effect of CD81 depletion on the major steps of the influenza
infection. We found that CD81 primarily affected virus infection at two stages: viral uncoating during entry and virus
budding. CD81 marked a specific endosomal population and about half of the fused influenza virus particles underwent
fusion within the CD81-positive endosomes. Depletion of CD81 resulted in a substantial defect in viral fusion and infection.
During virus assembly, CD81 was recruited to virus budding site on the plasma membrane, and in particular, to specific sub-
viral locations. For spherical and slightly elongated influenza virus, CD81 was localized at both the growing tip and the
budding neck of the progeny viruses. CD81 knockdown led to a budding defect and resulted in elongated budding virions
with a higher propensity to remain attached to the plasma membrane. Progeny virus production was markedly reduced in
CD81-knockdown cells even when the uncoating defect was compensated. In filamentous virus, CD81 was distributed at
multiple sites along the viral filament. Taken together, these results demonstrate important roles of CD81 in both entry and
budding stages of the influenza infection cycle.
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Introduction
Influenza virus, the major causal agent of flu, is an enveloped,
negative-sense RNA virus containing three viral membrane
proteins: hemagglutinin (HA), neuraminidase (NA), and M2
proton channel. Encapsulated within the viral envelope is a layer
of matrix protein (M1) and a segmented genome. The eight single-
stranded RNAs package into viral ribonucleoprotein complexes
(vRNPs), each attached to a RNA-dependent RNA polymerase
complex with three subunits: PA, PB1, and PB2 [1].
As an obligatory pathogen that encodes only 13 viral proteins,
influenza virus must rely on host proteins and cellular machinery
to complete its infection cycle. Influenza infection begins with virus
binding to sialic acids on the plasma membrane [2]. Virus-
receptor interaction subsequently triggers viral entry through
multiple endocytic routes including clathrin-mediated endocytosis,
a clathrin/caveolin-independent pathway, and macropinocytosis
[3–7]. Upon internalization, virus particles are trafficked from
early endosomes to maturing endosomes, where fusion between
the virus and endosomal membranes results in release of vRNPs
into the cytoplasm followed by nuclear import of the vRNPs [1,
8–10]. As replication proceeds, viral mRNAs are exported out of
the nucleus for protein translation, and viral components are
trafficked to the plasma membrane, the site of virus assembly and
progeny virion egress [11].
Recently, several genome-wide siRNA screens identified host
factors exploited by influenza virus [12–16]. CD81 emerged as a
top candidate in two screens and was found to regulate early viral
entry steps [15,16]. CD81 belongs to the family of tetraspanins
and is expressed on both plasma and endosomal membranes [17–
19]. It associates with other tetraspanins and tetraspanin-
interacting proteins to form tetraspanin-enriched microdomains
[18,20,21]. Together, these proteins regulate many cellular
processes such as cell adhesion, cell signaling, cell migration, and
protein trafficking [18,19,22–24]. Tetraspanins are known to play
an important role in different steps of viral infection [25]. For
example, CD81 functions as a co-receptor for hepatitis C virus
(HCV) [26–29]. CD81 interacts with HCV glycoprotein E2 to
prime the virus for low-pH dependent fusion during entry
[26,30,31]. In addition to mediating viral entry, CD81 is also
potentially involved in viral assembly. CD81 is one of the cell-
derived components incorporated into purified influenza virus
PLOS Pathogens | www.plospathogens.org 1 October 2013 | Volume 9 | Issue 10 | e1003701
particles [32]. It is however unknown how CD81 facilitates
influenza viral entry, or whether CD81 plays a functional role in
influenza virus assembly.
We conducted a comprehensive study from viral entry to egress
to examine the effect of CD81 depletion on influenza infection.
Upon dissecting each of the major steps in influenza infection
pathway, we found that CD81 was required for productive viral
infection and that CD81 primarily functions at two stages: viral
fusion within endosomes and virus budding. About half of the
influenza virus particles that fused in cells underwent fusion within
CD81+ endosomes, and CD81 depletion led to a decrease in virus
fusion and infection. CD81 was highly enriched in the virus
budding zones and recruited to specific sub-viral locations. During
virus assembly, CD81 initially formed small clusters at the growing
tip of assembling virus, and then localized at both the growing tip
and budding neck of spherical or slightly elongated virions. CD81
depletion led to an increase in the propensity of budding virions to
remain attached to the plasma membrane and a reduction in
progeny virus production. These findings demonstrate a dual
function of CD81 in both entry and budding of influenza viruses.
Results
CD81 is involved in both early and late stages of
influenza virus infection
To elucidate the role of CD81 in influenza virus infection, we
used CD81 knockdown by siRNA to probe the effect on three
different influenza A virus strains: influenza A/WSN/33 (H1N1),
a lab-adapted strain that mainly produces spherical virus particles;
influenza A X-31, A/Aichi/68 (H3N2) which has a slightly
elongated shape [33]; and influenza A/Udorn/72 (H3N2), which
can produce long filamentous virus [34–37]. We screened six
CD81 siRNA constructs, including several previously reported
ones [15,16], and found that CD81 siRNA 1 gave the highest
knockdown efficiency (Figure 1A, B and Figure S1A, B). After
48 hours, siRNA 1 yielded 80–85% CD81 knockdown (Figure
S1C). Treatment with siRNA 1 specifically depleted CD81,
whereas the expression levels of several known CD81-associating
proteins, including CD9, CD82, CD63, integrin b1 (ITGB1),
EGFR, and EWIF, were not affected (Figure S1D). In subsequent
experiments, we used siRNA 1 to deplete CD81 in A549 lung
carcinoma cells.
To assay the effect of CD81 depletion on the production of
infectious viral progeny, siRNA-treated A549 cells were infected
with WSN, X-31 or Udorn virus at a MOI of ,0.1 for 36 hours.
The virus titer of the supernatant was determined using plaque
assays. Compared to the non-targeting control siRNA treated
cells, the CD81-knockdown cells exhibited a substantial decrease
in virus titer: ,90% decrease for WSN, ,75% decrease for X-31,
and ,70% decrease for Udorn (Figure 1C). These results are
consistent with the previously published data [15,16], and indicate
that multiple different influenza strains require CD81 for infection.
Next, we proceeded to determine which stage(s) of the multi-
step influenza-infection process is CD81-dependent. To test
whether CD81 affects early infection, we infected siRNA-treated
A549 cells and measured the expression of NP, the first viral
protein expressed in influenza-infected cells [15,16,38]. We
assayed the fraction of cells that express NP (NP+) as well as the
level of NP expression in each NP+ cell using flow cytometry. For
all three viral strains, CD81-knockdown cells had ,50% fewer
NP+ cells, as compared to non-targeting siRNA treated control
cells (Figure 1D). Among the NP+ cells, the NP expression level
was similar between control and CD81-knockdown cells (data not
shown). These results suggest that CD81 is involved in early
infection either at the step of or prior to viral protein expression.
In order to test whether CD81 directly affects viral protein
expression, we next induced viral fusion (uncoating) at the plasma
membrane through an acid-bypass treatment: treatment with a
buffer of pH below 5, the pH value required for HA-induced
membrane fusion. We then probed the expression of NP in these
samples. The fraction of NP+ cells and the level of NP expression
were similar between control and CD81-knockdown cells infected
by the virus using the acid-bypass treatment (Figure 1E and data
not shown). These results suggest that CD81 is not directly
involved in the viral protein expression, and the inhibition of virus
infection by CD81 knockdown was most likely due to inhibition of
viral uncoating in endosomes or any step prior to uncoating. It is
worth noting that this acid-bypass assay overcame the entry defect
for the WSN and X-31 strain, but a similar acid bypass treatment
did not work for the Udorn strain, likely because low pH causes
fragmentation of filamentous influenza viruses [7].
To probe whether CD81 plays additional roles beyond viral
uncoating, we induced influenza viral fusion at the plasma
membrane using the acid-bypass treatment to overcome the entry
defect, and determined the virus titer of the supernatant 17 hours
post-infection. Notably, as compared to control siRNA treated
cells, the virus titer was decreased by more than 50% in the CD81-
knockdown cells (Figure 1F). This defect did not result from a
decrease in viral gene expression, as the percent of viral protein
expressing cells and the expression level at 17 hours post-infection
were unaffected upon CD81 knockdown (Figure 1E and data
shown later). These results suggest that CD81 affects another step
post viral gene expression.
Taken together, the above results indicate that CD81 is
important for two distinct stages of the influenza infection cycle:
one during the early infection at or prior to viral uncoating and
one during late infection after viral gene expression. In the
following experiments, we aimed to identify the specific roles of
CD81 in influenza virus infection.
CD81 is not involved in virus binding, internalization or
trafficking to early endosomes
To identify the CD81-dependent entry step(s), we conducted a
series of experiments to examine the effect of CD81 on virus
binding, internalization, transport into early endosomes, and
fusion. siRNA-treated A549 cells were first incubated with
fluorescently labeled X-31 virus for 30 minutes at 4uC, a
temperature that inhibits endocytosis. The amount of surface-
bound virus was analyzed through flow cytometry. CD81-
knockdown cells exhibited no defect in binding with influenza
Author Summary
As a ‘‘Trojan Horse’’ that only encodes 13 viral proteins,
influenza hijacks host cell machinery for productive
infection. In this work, we studied the role of the host
protein CD81 in influenza infection. We found that CD81
was important for influenza infection at two distinct
stages: virus uncoating and virus budding. Specifically,
during virus entry, more than half of internalized virus
particles were trafficked into a specific CD81-positive
endosomal population for virus uncoating. Depleting
CD81 led to a significant defect in viral uncoating and
infection. During virus egress, CD81 was recruited to virus
assembly site, and incorporated into individual virions at
specific sub-viral locations. CD81 depletion resulted in
virions that failed to detach from the plasma membrane
and a marked decrease in progeny virus production.
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viruses when compared to control cells treated by non-targeting
siRNA (Figure 2A). Next, influenza virus infection was allowed to
proceed for 30 minutes at 37uC, and the number of internalized
virus particles was quantified. As shown in Figure 2B, the number
of internalized viruses per cell was similar between control and
CD81-knockdown cells. Moreover, virus particles in both control
and CD81-knockdown cells were delivered into early endosomes
after internalization at 37uC. At 20 minutes post infection, the
mean fraction of virus particles colocalized with early endosomes
(marked by EEA1) was ,50% and ,53% for control and CD81-
knockdown cells, respectively (Figure 2C). These results suggest
that CD81 does not affect trafficking of influenza virus to early
endosomes.
Additionally, we tested the effect of CD81 depletion on two
other viruses: respiratory syncytial virus (RSV) and GFP-encoding
pseudotyped murine leukaemia virus (MLV), which are known to
Figure 1. CD81 is involved in both early and late stages of influenza virus infection. A) A549 cells were treated with non-targeting control
siRNA, or CD81 siRNA1 for 48 hours and immunostained with anti-CD81 antibody. Images are maximum projections of confocal z-stacks. B) A549 cells
were treated with control or CD81 siRNA for 48 hours. Cells were harvested for western blotting with indicated antibodies. Tubulin was used as a
loading control. C) Influenza virus infection is impaired by CD81 depletion. A549 cells were treated with siRNAs or mock treated for 48 hours and
subsequently infected with X-31, WSN, or Udorn at a MOI of ,0.1 for 36 hours. The viral titer in the supernatant was determined by plaque assays.
The shaded bar indicates the infectivity measured in cells mock treated with a transfection solution that contains no siRNA; the hollow bars indicated
the infectivity measured in cells treated with control, non-targeting siRNA; the black solid bars indicate the infectivity measured in cells treated with
CD81 siRNA. D) The number of infected cells expressing viral NP is reduced by about 50% upon CD81- knockdown. siRNA-treated A549 cells were
infected with WSN, X-31, or Udorn viruses with a MOI of ,0.1 for 8 hours without acid bypass and the fraction of cells expressing NP was measured
through flow cytometry. E) Viral NP expression is unaffected upon CD81 knockdown when influenza infection is induced by the acid-bypass
treatment to eliminate the entry defect. siRNA-treated A549 cells were allowed to bind with WSN or X-31 virus on ice for 1 hour, treated with warm
low pH PBS buffer (pH 4.5) for 2 minutes. After 8 hours, cells were collected and stained against NP for flow cytometry analysis. F) Virus titer in the
supernatant is reduced by,50% or more in CD81-knockdown cells infected by influenza viruses through the acid-bypass treatment. Briefly virus was
allowed to bind with control or CD81-knockdown cells on ice for 1 hour. Unbound virus particles were washed out and low pH buffer was added in
for 2 minutes to trigger virus fusion at the plasma membrane. At 17 hours post infection, supernatant was collected and the viral titer was assayed by
plaque assay. For figure 1C–1F, the error bars are standard deviation derived from three independent experiments. A two-tailed student t-test was
performed for all of the numerical data, and the p value of the data is shown. A p value smaller than 0.05 indicates there is a statistically significant
difference.
doi:10.1371/journal.ppat.1003701.g001
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undergo virus fusion in early endosomes in a pH-independent
manner [39,40]. Pseudotyped MLV infected cells express GFP,
but cannot produce complete virions, allowing the quantification
of MLV entry through measuring the GFP expression. For RSV,
we measured the expression level of the fusion protein (F protein)
after 24 hours of infection. As shown in Figure 2D, the fraction of
infected cells was similar between control and CD81-knockdown
cells with MLV and RSV infection. This data further corroborates
the notion that CD81 does not affect virus trafficking into early
endosomes.
Taken together, the results presented above indicate that CD81
is not involved in influenza virus binding, internalization, or
trafficking into early endosomes.
Influenza virus particles are delivered to and fuse in
CD81+ endosomes
Next, we probed the role of CD81 in virus fusion. Influenza
virus is trafficked from early endosomes to maturing endosomes, in
which the low pH environment triggers conformational changes in
HA that mediate viral fusion with the endosomal membrane
[2,9,41]. In addition to being distributed on the plasma
membrane, CD81 also showed substantial colocalization with
early and maturing endosomes, which are Rab5 positive (Rab5+)
(Figure 3A) [41]. About 30–35% Rab5+ endosomes contained
CD81 (Figure 3A), suggesting that CD81 is enriched in a sub-
population of these endosomes. To probe whether influenza virus
particles are delivered into CD81+ endosomes, we allowed Alexa
Fluor 647-labeled X-31 to internalize for 15 minutes and
immunostained the cells for CD81. As shown in Figure 3B, a
substantial fraction (,54%) of virus colocalized with CD81+
endosomes.
We then tracked individual influenza virus particles in living
cells, a technique that has been previously established [5,10,41–
43], to examine whether influenza viruses fuse in CD81+
endosomes. To this end, we expressed CD81-mEmerald in A549
cells. Similar to endogenous CD81, CD81-mEmerald was
Figure 2. CD81 is not required for virus binding, internalization or delivery into early endosomes. A) CD81-knockdown does not affect
virus binding, as measured by flow cytometry. The magenta, blue and orange curves correspond to the intensity profiles measured for cells without
adding viruses, control cells after influenza virus binding, and CD81-knockdown cells after influenza virus binding, respectively. B) The number of
virus particles internalized is not affected by CD81 knockdown. The number of internalized virus particles was shown in a dot plot, with the middle
line representing the mean value, and top/bottom line representing standard deviation. At least 40 randomly chosen cells were analyzed for each
condition. C) The percent of virus particles colocalizing with early endosome is not affected by CD81 knockdown. Early endosomes were
immunostained with anti-EEA1 antibody. Data was plotted similarly as in (B). At least 40 randomly chosen cells were analyzed for each condition. D)
CD81 depletion does not affect RSV or pseudo-typed MLV infection. siRNA-treated A549 cells were infected with different doses of RSV and pseudo-
typed MLV virus for 24 hours. For RSV virus infection, RSV fusion protein expression was quantified by flow cytometry, while for pseudo-typed MLV
virus, the GFP signal was analyzed. A two-tailed student t-test was performed for all of the numerical data, and the p value of the data is shown.
doi:10.1371/journal.ppat.1003701.g002
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Figure 3. A major fraction of viruses are trafficked to and fuse in CD81-positive endosomes. A) CD81 substantially colocalizes with Rab5.
A549 cells were electroporated with CD81-mEmerald and RFP-Rab5. At 24 hours, the cells were fixed and imaged. An enlarged image of the boxed
region is shown on the right. Scale bar: 10 mm. B) Influenza virus particles traffick into CD81+ endosomes. A549 cells were cold bound with Alexa
Fluor 647-labeled X-31 virus (red) on ice for 30 minutes and then chased for 15 minutes at 37uC. The samples were fixed and immunostained against
CD81 (green). An enlarged image of the boxed region is shown on the right. All of the images are confocal XY cross sections. Scale bar: 10 mm. C) An
Role of CD81 in Influenza Virus Infection
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localized on both plasma and endosomal membranes (Figure S2A)
and the expression of CD81-mEmerald did not affect the fraction
of endosomes that are CD81+ (Figure S2B–D). Moreover, the
expression of CD81 also did not affect influenza viral fusion or
infectivity (Figure S2E, F).
To facilitate tracking of individual virus particles, X-31 viruses
were labeled with a saturating amount of DiD, a lipophilic dye, such
that the fluorescence emission from the DiD molecules was low due
to a self-quenching effect between neighboring dyes. Fusion
between the virus envelope and endosomal membrane should lead
to an increase in fluorescent intensity (dequenching), due to the
diffusion of dyes from the virus into the lipid bilayer of the
endosomes [42]. We added labeled viruses to the CD81-mEmerald
expressing cells in situ at 37uC. The virus particles typically show
restricted movement immediately after binding to the cell, followed
by rapid and directed movement once the virus particles are
internalized, similar to our previous observations [5,41,42]. We
observed a proportion of virus particles entering into CD81+
endosomes soon after internalization, as illustrated by the example
shown in Figure 3C and movie S1. These viruses remained
colocalized with CD81 and eventually fused with the CD81+
endosomes, as reflected by the sudden increase of DiD fluorescence,
presumably after the endosomes matured to acquire a sufficiently
low pH (Figure 3C and movie S1). Among the 61 virus particles that
we tracked from binding to fusion, about 5268% underwent viral
fusion within CD81+ endosomes (Figure 3E). The remaining
4868% of virus particles fused in endosomes lacking CD81
(Figures 3D,E, and movie S2). To confirm that the fusion events
indeed occurred in endosomes, we tracked individual DiD-labeled
influenza virus particles in cells expressing RFP-Rab5. Similar to
previous observations [41], nearly 90% of the viral fusion events
occurred in Rab5+ endosomes (Figure S3).
To investigate whether CD81 affects viral fusion, we next
monitored the DiD fluorescent intensity in control and CD81-
knockdown cells that were infected with DiD-labeled X-31 virus.
In these experiments, cells were first incubated with DiD-labeled
virus at 4uC and then the temperature was increased to 37uC to
initiate viral entry. At specific time points after the temperature
shift, infected cells were collected and the DiD fluorescence from
these cells was quantified with flow cytometry. As expected, there
was a consistent increase of DiD fluorescence with time due to
viral fusion (Figure 3F). Notably, compared to control cells, CD81-
knockdown cells exhibited a significant reduction in viral fusion
(Figure 3F), suggesting that CD81 facilitates viral fusion. Most of
the remaining viral fusion events in CD81-knockdown cells still
occurred in Rab5+ endosomes (Figure S3). The reduction in viral
fusion was, however, incomplete (Figure 3F), consistent with the
observation that only about half of the virus particles fuse in
CD81+ endosomes (Figure 3E), though the incomplete inhibition
of viral fusion could also be in part due to the incomplete
knockdown of CD81 (Figure S1).
These data indicate that CD81 marks a specific population of
Rab5+ endosomes that are responsible for half of viral fusion
events. Because CD81-knockdown cells reduced viral infection
(Figure 1C) and exhibited a higher reduction in virus titer when
infected without acid bypass than when infected with acid bypass
(Figures 1C,F), viral fusion within CD81+ endosomes likely leads
to productive influenza infection.
Taken together, our results indicate that half of virus particles
are trafficked to and undergo viral fusion in CD81+ endosomes.
CD81 could facilitate viral fusion by organizing endosomal
membrane to assist viral fusion or helping virus traffick to
fusion-competent endosomal compartments.
CD81 is not involved in the expression or trafficking of
viral proteins
In the subsequent experiments, we aimed to determine which
post-entry step(s) of the viral infection process are CD81
dependent. To this end, we examined the effect of CD81 on
viral protein expression, viral protein trafficking, and the
assembly and egress of progeny viruses. Our initial results in
Figure 1E suggested that CD81 knockdown did not directly
affect viral NP expression. This was further substantiated by
infecting cells with various viral doses across different time
points using the acid-bypass treatment. As shown in Figure 4A,
the fraction of NP+ cells and NP expression level increased with
the viral dose and infection time, while there was no significant
difference between control and CD81-knockdown cells. To
further validate the finding, we measured the expression of
another cytosolic viral protein, M1. Similar to the results on NP,
CD81-knockdown cells infected by influenza viruses using the
acid-bypass treatment did not exhibit a difference in the fraction
of M1+ cells or the level of M1 protein expression, when
compared to the control cells (Figure 4B). These data suggest
that CD81 does not play a role in viral gene expression for
cytosolic viral proteins.
To determine whether CD81 affects viral membrane protein
expression, we probed M2 expression with acid bypass treatment.
The fraction of M2+ cells and the M2 expression level in M2+ cells
were similar between control and CD81-knockdown cells
(Figure 4C). Furthermore, by only probing the surface M2 protein
without permeabilizing the cells, we found that there was no
difference in surface M2 protein expression level either (Figure 4D),
indicating that CD81 knockdown also did not affect the trafficking
of M2 to the cell surface. Similarly, the expression and trafficking
of another viral membrane protein, NA, were also not affected
upon CD81 depletion (Figure 4E).
Taken together, these data indicate that CD81 does not play a
direct role in the expression of influenza viral proteins or the
trafficking of influenza membrane proteins to the plasma
membrane.
influenza virus particle enters and fuses within a CD81-positive endosome after entry. Live-cell confocal imaging of DiD-labeled X-31 added in situ to
CD81-mEmearld expressing A549 cells maintained at 37uC. The images were collected with a 0.5 s interval. C-1) Several snapshots taken at different
time points with the virus indicated by the white circles. C-2) The fluorescence signal of the indicated DiD-labeled virus as a function of time. Note
that there is a sudden increase of DiD signal at 515 s, which indicates a viral fusion event. D) Influenza virus can also fuse in a CD81-negative
endosome. D-1) Several snapshots taken at different time points with the virus indicated by the white circles. D-2) The fluorescence signal of the
indicated DiD labeled virus as a function of time. The virus particle fused at 422 s. E) Among 61 virus particles tracked from binding to fusion, 5268%
enter and fuse within CD81+ endosomes whereas the remaining 4868% fuse in CD81- endosomes. The results are taken for four independent
experiments, and the 6error indicates the standard deviation derived from these experiments. F) Virus fusion is impaired upon CD81 depletion. DiD-
labeled X-31 was allowed to bind with A549 cells on ice for 30 minutes, and then chased for the indicated times at 37uC. Cells were trypsinized and
fixed immediately, and analyzed by flow cytometry. The increase in the DiD intensity versus the initial DiD intensity is plotted. The error bars are
standard deviation derived from duplicate experiments.
doi:10.1371/journal.ppat.1003701.g003
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CD81 is recruited to influenza virus budding sites on the
plasma membrane
Next, we probed the role of CD81 in virus assembly. To test
whether CD81 is present at the viral assembly sites, A549 cells
were infected with the three influenza strains and immunostained
for CD81 and the viral protein. Notably, with X-31 infection,
CD81 was mostly localized to a site concentrated with multiple
viral proteins (Figures 5A and S4A, B). In contrast to uninfected
cells, which showed a uniform distribution of CD81 on the plasma
membrane, X-31-infected cells exhibited marked redistribution of
CD81 into concentrated patches. All of the X-31 proteins that we
could obtain specific immunofluorescence staining for, including
PB1, NA and M2, were present in these patches. The CD81
patches were formed on the plasma membrane, as confirmed by
immunofluorescence of non-permeabilized cells (Figure S4B). We
note that there was only a modest decrease of CD81 expression
upon viral infection (Figure S5A, B). For Udorn-infected cells,
CD81 was enriched along the budding virus filaments marked by
PB1 (Figure 5B). PB1 is a good filament marker that colocalized
with Udorn HA and M2 in the budding filamentous virions
(Figure S4C,D). We have also directly observed colocalization
between CD81 and other Udorn proteins including HA, NA and
an anti-Udorn serum (Figure S4E–G). Remarkably, upon siRNA
treatment, which depleted 80,85% of the endogenous CD81, the
remaining CD81 was all concentrated in the budding viral
filaments, whereas the cell body had little CD81 signal (Figures 5C
and S4H). The average amount of CD81 per virus filament in the
CD81-knockdown cells was reduced by more than 60% compared
to that in control cells. Although our lack of WSN antibodies made
it difficult to perform similar immunofluorescence experiments on
WSN-infected cells, our EM images with CD81 labeled by
immunogold showed that CD81 was also recruited to the WSN
virus budding zones (Figure S6A). Taken together, these results
indicate that CD81 is specifically recruited to the influenza virus
assembly and budding sites.
To probe which viral component may be responsible for
recruiting CD81, we turned to a plasmid-based system that
expresses only specific viral envelope proteins in cells [44]. We
transiently transfected the plasmid containing HA or NA in A549
cells and immunostained the cells with CD81 and HA or NA.
Interestingly, HA tends to form clusters on the cell surface even
when expressed alone in A549 cells and CD81 accumulated
substantially in the HA clusters (Figure S7A). About 46% of HA
clusters colocalized with CD81. In contrast, NA when expressed
alone did not form clusters but was distributed largely uniformly
across the plasma membrane and there was no appreciable
correlation between the CD81 distribution and NA distribution
(Figure S7C). Mock transfection with plasmid that did not contain
HA or NA did not yield any appreciable HA or NA staining
(Figure S7B,D). These results suggest that HA is likely responsible
for recruiting CD81 to the viral budding sites.
CD81 is incorporated at specific sub-viral locations and
facilitates influenza virus budding
Although we observed a ,50% or more decrease in virus titer
in CD81-knockdown cells after acid-bypass treatment to overcome
the CD81-dependent entry defects (Figure 1F), it remained
unknown whether the defect in viral titer stems from a decrease
in the number of budding virions assembled on the cell, the
number of progeny virus particles released from the cell, or the
specific infectivity per released virus particle. To distinguish
between these possibilities, we first infected cells using the acid-
bypass treatment and then quantified the number of budding
virions attached to the cells using transmission electron microsco-
py. After quantifying more than 250 cell cross-sections per
condition, we performed statistical analysis and found no
statistically significant difference in the number of assembling
virus particles per cell cross-section in the control versus CD81-
knockdown cells (Figure 6A).
Next, we infected cells with WSN using the acid-bypass
treatment, collected the virus particles in the supernatant, and
then quantified the amount of viral matrix protein M1 using an
ELISA assay and the number of released virus particles positive of
both M1 and HA using an imaging assay (Figure 6B). Notably,
compared to control cells treated by non-targeting siRNA, CD81-
knockdown cells exhibited 50% or more decrease in both the
amount of viral M1 and the number of M1+ and HA+ virus
particles released into the supernatant. These results suggest that
the CD81-knockdown-induced reduction in viral titer in cells
infected by the acid-bypass treatment stems from a defect in virus
release. Given that the reduction in viral titer (Figure 1F) was
similar to the reduction in the amount of released viral proteins or
viral particles (Figure 6B), we did not further probe the change in
specific infectivity per virus particle.
To examine how CD81 may facilitate release of progeny virus
particles, we next probed the distribution of CD81 within
individual budding virions using immunogold electron microsco-
py. In X-31-infected cells, CD81 was readily observed in budding
virions (Figure 6C, D). During early assembly stages, CD81
clusters located at the growing tip of budding virions (Figure 6C).
Interestingly, when viruses grew into a mature, slightly elongated
shape [33], CD81 was not only found on the growing tip, but also
on the neck of budding virions (Figure 6D). The elongated
morphology of X-31 allowed us to quantitatively analyze the
CD81 distribution in virions by aligning the long axis of the virus
particles and normalizing the position of immunogold-labeled
CD81 to the total length of the virus. Remarkably, CD81 is highly
enriched at the two ends of the budding virions (Figure 6D, E).
Figure 4. CD81 depletion does not affect viral protein expression and transport. A) CD81 knockdown does not affect the expression of
viral NP protein in cells infected by influenza viruses with the acid-bypass treatment. Experiments were performed similarly as in 1E) except that the
expression levels are evaluated at different time point post infection and with different dose of viruses. The percent of NP-expression cells and the NP
expression level in NP+ cells are plotted. B) CD81 knockdown does not affect the expression of viral M1 protein in cells infected by influenza viruses
with the acid-bypass treatment. Experiments were performed similarly as in (A) except cells were immunostained for M1. The percent of M1+ cells
and the M1 expression level in the M1+ cells are plotted. C) CD81 knockdown does not affect the expression of viral M2 protein in cells infected by
influenza viruses with the acid-bypass treatment. Experiments were performed similarly as in (A) except cells were immunostained for M2. The
percent of M2+ cells and the M2 expression level in the M2+ cells are plotted. D) CD81 knockdown does not affect the amount of M2 protein
trafficked to the cell surface in cells infected by influenza viruses with the acid-bypass treatment. Experiments were performed similarly as in (C)
except cells were stained for M2 without permeabilization. The percent of M2+ cells and the surface M2 expression level in M2+ cells are plotted. E)
CD81 knockdown does not affect the amount of NA protein trafficked to the cell surface in cells infected by influenza viruses with the acid-bypass
treatment. The NA expression level was estimated from confocal images in control or CD81 siRNA treated cells infected by X-31virus. A two-tailed
student t-test was performed for all of the numerical data, and the p value of the data is shown.
doi:10.1371/journal.ppat.1003701.g004
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Similarly, we also found CD81 to be enriched in budding WSN
virus particles, but the quantity of immunogold detected per WSN
virus is substantially lower than that in X-31 viruses, which made it
difficult to determine the CD81 distribution in these viruses
(Figure S6A). However, the nearly perfectly spherical shape of the
WSN virus allowed us to detect an interesting morphological
defect of budding viruses in CD81-knockdown cells. When we
examined budding virions in cells infected by WSN, we found that
most budding WSN viruses were spherical and completely
enclosed by viral envelope in control cells treated by non-targeting
siRNA (Figure 6F). In stark contrast, budding WSN virus in
CD81-knockdown cells appeared much more elongated
(Figure 6G). The average length of budding virions in control
and CD81-knockdown cells was ,100 nm and ,150 nm,
respectively (Figure 6H). Furthermore, many budding viruses in
CD81-knockdown cells did not have a fully enclosed envelope but
remain attached to the plasma membrane through an open
membrane neck (indicated by arrowheads in Figure 6G). We
performed similar experiments with the X-31 strain. Again, we
consistently observed many budding X-31 virions with the open
budding neck defect upon CD81 depletion (Figure S6B, C),
though characterizing whether the budding virions were further
elongated was difficult due to the large variation of the virion
length of the pleomorphic X-31.
Taken together, the specific enrichment of CD81 at the neck of
the budding virions, the defect in budding neck closure in CD81-
knockdown cells, and the reduction in the number of released virus
particles but not in the number of assembling virions upon CD81
knockdown suggests that CD81 plays a role in a late stage of the
virus budding process, likely at the final scission step. CD81 may
Figure 5. CD81 is recruited to the virus budding sites. A) CD81 is recruited to the virus budding zone in X-31 infected cells. A549 cells were
infected with X-31 for 16 hours. Cells were stained with anti-CD81 antibody (green) and anti-PB1 antibody (red). Images are confocal XY cross-
sections. Scale bar: 10 mm. B) CD81 is incorporated into budding filamentous virions of Udorn-infected cells. A549 cells were infected with Udorn virus
for 16 hours, and stained with anti-CD81 antibody and anti-PB1 antibody. Scale bar: 10 mm. C) Remaining CD81 in CD81-knockdown cells is
incorporated into budding filamentous viruses of Udorn infected cells. Similar to (B) except that CD81-knockdown cells were used. The CD81
expression level in Udorn-infected cells was calculated based on confocal images of more than 100 cells, and was found to be decreased by ,88%
upon CD81 depletion as compared to control cells. The amount of CD81 per viral filament was reduced by 63% compared to that in untreated cells.
Scale bar: 10 mm.
doi:10.1371/journal.ppat.1003701.g005
Role of CD81 in Influenza Virus Infection
PLOS Pathogens | www.plospathogens.org 9 October 2013 | Volume 9 | Issue 10 | e1003701
Role of CD81 in Influenza Virus Infection
PLOS Pathogens | www.plospathogens.org 10 October 2013 | Volume 9 | Issue 10 | e1003701
facilitate viral scission by directly participating in the scission
process, by recruiting host or viral scission proteins, or by organizing
the lipid domains and making it conducive to viral scission.
Distribution of CD81 in budding filamentous Udorn virus
Unlike WSN and X-31 strain, Udorn virus infection typically
produces filaments that can reach 2 to 20 mm long [11,35,45,46].
We visualized immunogold-labeled CD81 distribution in A549
cells infected by Udorn virus with electron microscopy and
observed CD81 clusters in budding viral filaments. Notably, CD81
appeared to be distributed along the entire Udorn filament
(Figure 7A).
As an alternative approach, we used a super-resolution fluores-
cence imaging technique, Stochastic Optical Reconstruction
Microscopy (STORM), to measure the distribution of CD81 on
the budding filament. STORM overcomes the diffraction limit of
light microscopy by sequentially activating, imaging and localizing
individual fluorescent photoswitchable molecules at high precision,
thereby reconstituting images from the molecular localizations with
nano-meter scale resolution [47,48]. Here, we used a single-
objective detection geometry and photoswitchable Alexa Fluor 647
and Atto 488 dyes to obtain a lateral resolution of 20–30 nm and
axial resolution of 50–100 nm [48,49]. To visualize the localization
of CD81 in filamentous Udorn, we immunostained CD81 and viral
PB1, and performed two-color 3D STORM imaging. Consistent
with the results from electron microscopy (Figure 7A), we found that
CD81 formed small clusters evenly distributed along the entire
filament (Figure 7B). Adjacent CD81 clusters were usually separated
Figure 6. CD81 is enriched at specific sub-viral sites of budding virions and CD81 knockdown impairs virus scission. A) CD81
knockdown does not change the number of budding virions attached to infected cells. siRNA-treated cells were infected with WSN virus with the
acid-bypass treatment for 15 hours. Cells were directly fixed for transmission electron microscopy and the number of budding virus particles per cell
cross-section is quantified for over 250 sections, and presented in the dot plot. A two-tailed student t-test was performed and the p value is provided.
B) CD81 knockdown causes a substantial reduction in the number of released virus particles. siRNA-treated cells were infected with WSN virus with
the acid-bypass treatment for 17 hours. The amount of viral M1 protein in the supernatant was probed with ELISA. The number of M1 positive and
HA positive virus particles in the supernatant was counted using immunofluorescence imaging. The error bar is standard deviation from three
independent measurements. C) CD81 localizes at the tip of growing X-31 viruses during the early budding stages. Cells were infected with X-31 for
12 hours and CD81 was immunogold labeled for electron microscopy. An enlarged image of the area in the white box is shown in the upper right
corner. Scale bar: 100 nm. D) CD81 mainly localizes at the tip and budding neck of the X-31 viruses during late budding stages. Similar to (C) except
the infection time was 16 hours. Scale bar: 200 nm. E) Distribution of gold particles in budding X-31 viruses at 16 hour post infection. To align the
virus particles, the length of each virus is normalized to 1, with its middle point assigned with coordinate value of 0. For individual gold particles on
the budding virus, their coordinate values were calculated based on their relative distance to the middle point. Coordinates with negative values
correspond to positions close to the plasma membrane. A total of 105 budding viruses were analyzed. F) Budding WSN viruses exhibit a spherical
morphology with fully enclosed membrane envelope in control siRNA-treated cells. A549 cells were infected with virus with the acid-bypass
treatment for 13 hours. The region in the white box is magnified and shown in the upper right corner. Scale bar: 200 nm. G) Budding WSN viruses are
more elongated in CD81 siRNA treated A549 cells. A substantial fraction of budding viruses have an open membrane neck connected to the plasma
membrane (indicated by arrowheads). The region in the white box is magnified and shown in the upper right corner. Scale bar: 200 nm. H) Budding
WSN viruses are elongated upon CD81 depletion, as shown by the distribution of budding virus length in control or CD81-knockdown cells.
doi:10.1371/journal.ppat.1003701.g006
Figure 7. Scattered distribution of CD81 along budding filamentous Udorn virus. A) CD81 localizes along the filament of budding Udorn
viruses. A549 cells were infected with Udorn virus for 18 hours and CD81 was immunogold labeled for electron microscopy. Shown here is a bundle
of virus filament budding from the cell (the cell is not shown in order to magnify the virus filaments). Scale bar: 200 nm. B) CD81 and viral PB1
proteins appear to take an alternating distribution along filamentous Udorn virus. A549 cells were infected with Udorn virus for 16 hours and
immunostained with anti-CD81 (green) and anti-PB1 (red) antibodies. CD81 was further probed with Alexa Fluor 405/Alexa Fluor 647-conjugated
secondary antibody while PB1 was labeled with Atto 488 conjugated antibody for two-color 3D STORM imaging. Two example filamentous viruses
were shown in B-1) and B-2). Left: xy projection images. Middle) xz projection images. Right) Localization distribution of CD81 and PB1 along the
filament long axis. Scale bar: 500 nm.
doi:10.1371/journal.ppat.1003701.g007
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by about 150,200 nm. Curiously, CD81 appeared to be enriched
between clusters of viral PB1 proteins (Figure 7B), but the
significance of this alternating pattern is unclear.
Discussion
CD81, a cellular tetraspannin protein, is critical for influenza
viral infection [15,16]. The infectivity of various strains of
influenza viruses is strongly inhibited when cellular CD81 is
depleted (Figure 1). In this work, we dissected the roles of CD81 on
individual steps along the infection pathway from virus entry to
egress. We found that CD81 plays functional roles in two separate
steps of viral infection: viral fusion and virus budding.
The role of CD81 in viral entry
The specific role of CD81 during influenza viral entry was
determined using a series of independent assays. First, knocking
down CD81 by siRNA led to ,50% decrease in the percent of
infected cells expressing viral proteins. The defect was not due to
direct regulation of viral protein expression by CD81, since viral
protein expression remained unchanged upon CD81 knockdown
when influenza infection was induced by the acid-bypass
treatment (Figure 1 and Figure 4). These results suggest that
CD81 mediates influenza virus entry prior to viral gene
expression. Next, CD81 knockdown did not affect virus binding,
internalization or trafficking to early endosomes (Figure 2), but
led to a significant defect in viral fusion (Figure 3). Furthermore,
single-virus tracking experiments showed that half of internalized
virus particles were trafficked into CD81-positive endosomes and
underwent viral fusion within these endosomes, whereas the
remaining half fused in CD81-negative endosomes (Figure 3).
Notably, the fraction of viral fusion events occurring within
CD81-positive endosomes correlated well with the 50% reduction
in the percent of infected cells expressing viral proteins upon
depletion of CD81, suggesting a role of CD81 in productive viral
uncoating. Altogether, these results indicate that CD81 plays a
role in influenza viral fusion. CD81 marks an endosomal route
for productive virus uncoating process, though a parallel CD81-
independent route also exists.
Interestingly, the role of CD81 in influenza virus entry appears
to differ from the role of CD81 previously observed in HCV and
HIV entry. As an essential co-receptor for HCV, CD81 is
important for the endocytosis of HCV [27,28,50,51]. Further-
more, CD81 interacts with HCV glycoprotein E2 and helps prime
its fusogenic activity for low-pH dependent viral fusion [26,30].
Moreover, CD81 negatively regulates HIV-cell fusion [52].
Incorporation of CD81 and CD81-associated tetraspanins sup-
presses the HIV-mediated cellular fusion processes [52,53]. On the
other hand, CD81 unlikely functions as a co-receptor or
attachment factor for influenza viruses because the internalization
of influenza viruses into cells does not require CD81. Influenza
viral fusion does not need to be primed by CD81 either, as acid
treatment is sufficient to trigger viral uncoating at the plasma
membrane in CD81-depleted cells. Instead, our results suggest a
role of CD81 in facilitating influenza virus fusion in endosomal
compartments. Given that CD81 and CD81-associating proteins
can organize membrane domains [17–20], CD81 may help
organize the endosomal membrane for assisting influenza viral
fusion. Alternatively, CD81 may play a role in trafficking influenza
to fusion competent endosomal compartments. CD81 is highly
enriched in multivesicular bodies (MVBs), an intermediate
endosomal organelle on the maturation pathway of late endo-
somes and lysosomes [54]. CD81 depletion may inhibit the
maturation of endosomes and thus compromise influenza virus
fusion with endosomes.
The role of CD81 in viral assembly
In addition to its role in virus uncoating, CD81 also plays a
functional role in a later stage of influenza infection post viral
fusion. The requirement of CD81 in a post-fusion stage was
evident from the finding that CD81 depletion led to a significant
decrease in virus titer even when the acid-bypass treatment was
used to induce viral uncoating at the plasma membrane, thereby
eliminating entry defects (Figure 1F). The decrease did not result
from a defect in expression of viral proteins or trafficking of viral
proteins to the plasma membrane (Figure 4), suggesting that the
perturbation likely occurred at the virus assembly stage. Further-
more, the average number of budding virions attached to each
infected cell did not change upon CD81 knockdown, whereas the
number of virus particles released into the supernatant markedly
decreased (Figure 6A, B). These results further narrowed the
involvement of CD81 to a relatively late stage of the budding
process, likely the scission step that severs the virus particle from
the host cells. Supporting this notion, CD81 was specifically
recruited to viral budding sites (Figure 5), and among the viral
proteins, HA is likely important for recruiting CD81 to the virus
budding sites (Figure S7). Interestingly, CD81 was specifically
enriched at the tip and budding neck of the spherical and slightly
elongated viruses (Figure 6C–E). Upon CD81 knockdown, the
budding spherical viruses exhibited a consistent change in
morphology: the budding virions appeared substantially elongated
compared to their counterparts in control cells and failed to detach
from the plasma membrane. Many budding viruses did not have
their budding neck closed, indicating a defect in the final scission
process (Figure 6F–H). Taken together, our observations indicate a
role of CD81 in scission process that severs the budding virions
from the plasma membrane. CD81 could be directly participating
in the scission process, recruiting other host or viral scission
proteins for this purpose, or organizing the membrane domain at
the budding site and making it conducive for viral scission.
It is interesting to compare the role of CD81 in the assembly of
influenza virus with that of other viruses. Previous studies have
shown that HIV envelope proteins associate with a few
tetraspanins, including CD81, and that HIV buds from the
tetraspanin-enriched microdomains [55–57]. However, the exact
role of CD81 in HIV egress remains unclear [53,58–61]. One
study reports that HIV infection is significantly impaired upon
CD81 depletion or treatment with anti-CD81 antibodies [61],
whereas two other papers report that depletion of tetraspanins
does not affect the efficiency of HIV release whereas overexpres-
sion of tetraspanins results in decreased infectivity in released
virions [53,59]. Tetraspanins have also been proposed to facilitate
cell-to-cell transmission of HTLV-1 infection [25]. The role of
CD81 in the egress of influenza virus appears different from these
previously reported roles of tetraspanins in HIV and HTLV-1
infection in that CD81 positively regulate viral scission.
It has been previously shown that influenza virus scission is
dependent on viral M2 protein [62]. During virus budding, M2 is
localized at the neck of budding viruses and mutation of its
amphiphilic tail at the C-terminus leads to a marked defect in virus
budding [62]. Interestingly, M2 is known to localize at the
interface between lipid rafts and non-rafts region, while CD81 is
partitioned into tetraspanin-enriched microdomains, a platform
that resembles lipid rafts [18]. Thus, it is possible that CD81
facilitates the recruitment of M2 to the budding neck of the
viruses. Future studies on the interaction between CD81 and M2
during the viral scission process would be of interest to further
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elucidate the mechanistic role of CD81. CD81 associates with
tetraspanins and other tetraspanin-interacting proteins to form
tetraspanin-enriched microdomains on cellular membranes
[18,20]. CD9, a tetraspanin that interacts with CD81, was
previously identified in the purified virus particles [32]. Our
preliminary results revealed that other tetraspanin family proteins
were also incorporated into budding viruses (data not shown).
Whether and how different components within the tetraspanin-
enriched microdomains cooperate with each other in facilitating
influenza virus budding remains an interesting question for future
investigations.
Materials and Methods
Cell culture, viruses and reagents
A549 lung carcinoma cells (ATCC) were cultured in high glucose
Dulbecco’s modified Eagle medium (DMEM; Invitrogen) contain-
ing 10% fetal bovine serum (Serum International), and antibiotics
(ATCC; 25 U/ml penicillin and 25 mg/ml streptomycin), and
maintained in humidified, 5% CO2 environment at 37uC. For
siRNA knockdown experiments, A549 cells were electroporated
with 100 pmol siRNA constructs using program
X-001 of Amaxa Lonza Nucleofector with Kit-T (Lonza, VVCA-
1002). Experiments were performed 48 hours post electroporation.
siGENOME non-targeting siRNA #1(Thermo Scientific) was used
as a control siRNA. Six CD81 siRNA constructs were designed with
the following sequences: CD81 siRNA 1: CACCU UCUAU
GUAGG CAUCU A dTdT(Thermo Scientific); CD81 siRNA 2:
AAGGA ACAUC AGGCA UGCUA A dTdT(Thermo Scientific);
CD81 siRNA 3: GGAAC AUCAG GCAUG CUAATT (Qiagen);
CD81 siRNA 4: CCUUC UAUGU AGGCA UCUATT(Qiagen);
CD81 siRNA 5: GCCCA ACACC UUCUA UGUATT (Ambion);
CD81 siRNA 6: CCACC UCAGU GCUCA AGAATT (Ambion).
Note that CD81 siRNA 1 and CD81 siRNA 2 have been confirmed
previously not to cause interferon-induced response [16]. For
plasmid expression, 2 mg plasmids were electroporated with a
similar procedure. The following plasmids were used in this study:
CD81-mEmerald (human tetraspanin CD81 was cloned into the C
terminal of mEmerald, with a 10 amino acid linker between
mEmerald and CD81), RFP-Rab5 (gift from Professor Ari Helenius,
Addgene, 14437 [63]), EYFP-Rab7 [41]), pCAGGS-HA/Ud and
pCAGGS-NA/Ud (gifts from Professor Michael Farzan, Scripps
Institute, FL).
The following viruses were used in this study: influenza virus X-31
was purchased from Charles River Laboratories; WSN and Udorn
virus strains were gifts from Professor Robert Lamb (Northwestern
University, Evanston, IL). Respiratory syncytial virus was purchased
from Virapur. Pseudo-typed MLV virus was a gift from Professor Nir
Hacohen (Broad Institute, Cambridge, MA).
The following primary antibodies were used in this study: mouse
anti-CD81 antibody (BD Biosciences, 555675), FITC-conjugated
anti-CD81 antibody (BD Bioscience, 551108), mouse anti-EEA1
(BD Biosciences, 610457), rabbit anti-EEA1 (Cell signaling,
3288s), rabbit anti-CD82 (Santa Cruz, c-16, SC-1087), mouse
anti-CD63 (Abcam, ab8219), rabbit anti-EWIF (Fitzgerald, 70R-
13159), mouse anti-ITGB1 (Millipore, MAB2253), mouse anti-
tubulin (Sigma, T5076), mouse anti-EGFR (BD bioscience,
610016), rabbit anti-actin(Abcam, ab8227), rabbit anti-CD9
(Santa Cruz, H-110, sc-9148), goat anti-Udorn serum (gift from
Professor Robert Lamb (Northwestern University, Evanston, IL)),
mouse anti-M1 antibody (AbD Serotec, MCA401), goat anti-M1
antibody (Abcam, ab20910), mouse anti-influenza virus M2
antibody [14C2] (Abcam, ab5416), mouse anti-influenza virus
NP antibody [AA5H] (Abcam, ab20343), mouse anti-Alexa Fluor
647 (Sigma, C1117), mouse anti-RSV fusion protein (AbD serotec,
MCA490), goat anti-influenza virus PB1 antibody (Santa Cruz,
vK-20), mouse anti-influenza virus HA antibody (Lifespan, LS-
C58889), rabbit anti-influenza virus NA (gift from Professor
Gillian Air (University of Oklahoma, Oklahoma, OK)).
The following secondary antibodies were used for immunoflu-
orescence with conventional light microscopy or immunogold
electron microscopy: Alexa Fluor 647 donkey anti-mouse (Jackson
ImmunoResearch, 715-605-150), Cy3 donkey anti-mouse (Jackson
ImmunoResearch, 715-165-150), Alexa Fluor 488 donkey anti-
mouse (Jackson ImmunoResearch, 715-545-150), Alexa Fluor 488
donkey anti-rabbit (Jackson ImmunoResearch, 711-545-152), Cy3
donkey anti-rabbit (Jackson ImmunoResearch, 711-165-152),
Alexa Fluor 647 bovine anti-goat (Jackson ImmunoResearch,
805-605-180), Alexa Fluor 488 bovine anti-goat (Jackson Im-
munoResearch,805-545-180), 6 nm gold conjugated goat anti-
mouse IgG (Jackson ImmunoResearch, 115-195-146).
The following secondary antibodies were used for immuno-
fluoresence with STORM: donkey anti-mouse (Jackson Immu-
noResearch, 715-005-150) labeled with Atto 488 or Alexa Fluor
405 and Alexa Fluor 647, Bovine anti-goat (Jackson ImmunoR-
esearch, 805-005-180) labeled with Atto 488 or Alexa Fluor 405
and Alexa Fluor 647. To label antibodies with Alexa Fluor 405
and Alexa Fluor 647, 80 ml antibody (1.3 mg/ml) were mixed with
10 ml 1M NaHCO3, 8 mg Alexa Fluor 405 and 1.2 mg Alexa Fluor
647 dissolved in DMSO for 30 minutes. To label antibodies with
Atto 488, the conditions were similar except 1.6 mg Atto 488 was
used for the labeling reaction. The mixture was then filtered
through a NAP-5 gel filtration column (GE Healthcare) to collect
labeled antibody. Atto 488 emitted about 1100,1300 photons per
switching cycle, which is significantly lower than that of Alexa
Fluor 647 (4000,5000 photons per switching cycle) [49].
Virus infection
For virus infection, A549 cells were first inoculated with
different doses of viruses diluted in DMEM (without serum) for
90 minutes at 37uC. Cells were washed with PBS twice to remove
unbound viruses, and subsequently incubated with pre-warmed
full DMEM medium and maintained at 37uC. For measuring the
influenza virus titer (X-31, WSN, and Udorn) without using the
acid-bypass treatment, a total of 36 hours were allowed for virus
infection before collecting the supernatant for the plaque assay as
described below. For RSV virus infection, A549 cells were infected
with RSV for 24 hours, followed by immunostaining with anti-
fusion protein (F protein) antibodies and analysis by flow
cytometry. For pseudo-typed MLV virus infection, a 24-hour
was allowed for infection and cells were directly fixed to assay the
GFP fluorescent intensity by flow cytometry.
To ensure equal amounts of viral entry in control and CD81
siRNA treated cells for post-entry studies, an acid-bypass
treatment was conducted to induce viral fusion at the plasma
membrane. siRNA treated A549 cells were allowed to bind with
influenza virus at 4uC for one hour. After extensive washes with
cold PBS, a pre-warmed low pH buffer (PBS, pH 4.5) was added
in for two minutes. The low pH buffer was then neutralized with
culture medium and cells were placed with pre-warmed fresh
culture medium afterwards. For measuring the influenza virus titer
(X-31 and WSN) with the acid-bypass treatment, a total of
17 hours were allowed for virus infection before collecting the
supernatant for the plaque assay.
Plaque assay
Cells were infected with influenza virus for indicated amounts of
time as described above and supernatant was collected to assay the
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virus titer at the end of each time point. Serial dilutions of the
supernatant were used to inoculate MDCK-Texas cells (Kind gift
from Robert Lamb) seeded in 6-well plates for 90 minutes at 37uC.
After washing with PBS twice, a 3 ml agar overlay of DMEM
containing 30% Noble agar (Affymetrix), antibiotics and 2 mg/ml
acetylated trypsin (Sigma) was placed on cells. The plates were
incubated at 37uC. After about two days, the agar disks were
removed carefully and cells were immediately stained with crystal
violet solution (1:1,000 V/W crystal violet, 30% ethanol in water)
for 10 to 15 minutes, which allowed for an easy quantification of
the number of plaques. Virus titer (PFU/mL) = number of
plaques/(dilution factor6inoculation volume (mL)). For each
condition, samples were tested with triplicates.
Influenza virus labeling
Influenza virus X-31 was either labeled with lipophilic dye DiD
(Invitrogen, D7757) or Alexa Fluor 647 (Invitrogen, A-20006) as
previously described [42]. For the labeling reaction, 100 ml of the
original virus stock (2 mg/ml protein concentration) was incubat-
ed with either 3 ml of 25 mM DiD or 3 mg Alexa Fluor 647
dissolved in DMSO for two hours or one hour respectively with
gentle vortexing in the dark at room temperature. Unincorporated
dye was removed by buffer exchange into the Hepes 145 buffer
(50 mM Hepes, pH 7.4, 145 mM NaCl) by using NAP-5 gel
filtration columns (GE Healthcare). The labeled virus was
aliquoted, snap-frozen in liquid nitrogen, and stored at 280uC.
Immediately before experiments, the labeled virus was thawed and
filtered through a 0.2 mm pore size syringe filter (Supor
membrane, Pall) to remove viral aggregates. Labeled viruses are
infectious, as confirmed with standard plaque assays (data not
shown).
Virus binding assay
Control or CD81-knockdown A549 cells were allowed to bind
with DiD-labeled X-31 diluted in DMEM (without serum) for
30 minutes at 4uC. After extensive washes with cold PBS to
remove unbound viruses, cells were trypsinized and immediately
fixed with 2% paraformaldehyde (PFA) for 20 minutes at room
temperature. After washing PFA away with PBS, the DiD
fluorescent intensity was measured by a flow cytometer (BD
bioscience). At least 10,000 cells were quantified for each
measurement. The data was analyzed via FlowJo.
Virus internalization assay
Control or CD81-knockdown A549 cells were allowed to bind
with 36104 PFU/ml Alexa Fluor 647-labeled X-31 virus diluted in
DMEM (without serum) on ice for 30 minutes at 4uC. After
extensive washes with cold PBS to remove unbound viruses, pre-
warmed full culture medium was added in and the virus was
allowed to internalize at 37uC for indicated amounts of time. At
the end of each time point, cells were washed with PBS, directly
fixed with 4% PFA for 20 minutes at room temperature. In order
to distinguish the surface-bound versus internalized virus particles,
a non-permeablizing immunofluorescence in the absence of
detergents was performed by using a mouse anti-Alexa Fluor
647 primary antibody (Sigma, C1117), followed by staining with
an Alexa Fluor 555-conjugated donkey anti-mouse secondary
antibody (Invitrogen, A31570). The samples were imaged using a
custom-built spinning disk confocal microscope. Non-internalized
virus particles were stained with both Alexa Fluor 647 and Alexa
Fluor 555, while the internalized virus particles—inaccessible to
the antibodies—exhibited only the Alexa Fluor 647 signal. To
quantify the number of particles internalized per cell, we used the
maximum z-projection of the confocal z-stacks, and counted both
the total number of virus particles (with Alexa Fluor647 signal) and
the number of non-internalized virus particles (with both Alexa
Fluor 647 and Alexa Fluor555 signals), and the number of
internalized particles (with Alexa Fluor 647 but not Alexa Fluor
555 signal). A low enough number of virus particles (,15 particles)
was internalized each cell to minimize the possibility of multiple
virus particles sorting into the same vesicle. Statistical analysis was
performed using a two-tailed student t-test.
Western blotting
Cell lysate samples were prepared with Laemmli sample buffer
(Bio-Rad, 161-037) and run on a 4–15% Tris-HCL polyacryl-
amide gel (Bio-Rad). After transferring the protein onto Hybond
polyvinylidene difluoride membranes (GE Healthcare), the mem-
brane was blocked with 5% nonfat-milk in TBS-Tween for 1 hour,
followed with incubation of primary antibody overnight at 4uC, a
three 10 minutes wash step with TBS-Tween, and a one hour
incubation of HRP-conjugated secondary antibody at room
temperature. The signal was detected with TMA-6 (TMA-100,
Lumigen) and developed to Kodak films. Note that CD81 and
CD63 could only be detected under non-reducing conditions.
Flow cytometry
For flow cytometry analysis, the procedures were similar to what
was previously described [64]. Briefly, for measuring total protein
expression level (CD81 or viral proteins), cells were collected and
fixed with 2% PFA for 20 minutes. After washing with PBS once,
cells were permeablized with buffer P (0.075% Saponin, 10% BSA
in PBS) for 20 minutes at room temperature. Cells were incubated
with primary antibodies diluted in buffer P (1:1,000) for 1 hour
and washed with buffer P three times before incubating with
secondary antibodies for another 45 minutes. Secondary antibod-
ies were also diluted with buffer P (1:1,000). After washing with
buffer P, cells were resuspended with PBS and then analyzed by
flow cytometry. The data was analyzed by FlowJo. Cells were
gated based on FSC and SSC scattering, and a histogram was
generated based on the fluorescence intensity profile. For cells that
were infected with influenza virus, a second gate was set based on
comparison of fluorescence intensity of uninfected versus infected
cells. The population that falls into the second gate corresponds to
the percent of infected cells in each sample, from which the mean
fluorescence intensity was analyzed to infer the viral protein
expression level. To probe surface protein expression, all steps
were similar except detergent was excluded.
Immunofluorescence
For imaging-based experiments, A549 cells seeded in Lab-Tek 8
well glass dishes were fixed with 4% PFA for 20 minutes at room
temperature. Unless specified, fixed cells were permeablized with
0.1% Triton-X100 in PBS for 5 minutes, washed with PBS twice
and incubated with blocking buffer PBSA (3% BSA in PBS, or 5%
bovine serum in PBS) for 30 minutes. Cells were then incubated
with primary antibodies diluted in PBSA (1:500) for 1 hour.
Followed by three PBS washes (5 minutes each), secondary
antibodies were added for another 1 hour. Afterwards, cells were
washed with PBS for three times again before imaging. For
STORM, a post-fixation step was followed with 3% PFA and
0.1% glutaraldehyde (GA) in PBS for 20 minutes. For immuno-
staining surface protein only, permeablization was not performed
after fixation. When antibody species conflict existed, labeled
primary antibodies (CD81-FITC, BD Bioscience; HA-Alexa Fluor
647) were used as needed.
To quantify the colocalization ratio between internalized virus
and cellular proteins (EEA1 and CD81), samples were prepared
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similarly as in virus internalization assay. After probing the
surface-bound virus particles with anti-Alexa Fluor 647 antibody,
cells were permeabilized with 0.1% Triton-X100 in PBS, and a
subsequent indirect immunofluorescence was performed to stain
against each protein. Images were acquired by confocal micros-
copy and at least 40,100 randomly chosen cells were analyzed
manually for each condition. Only internalized virus particles were
used to quantify the fraction of viruses colocalized with CD81 or
EEA1.
ELISA
Cells were infected with influenza virus with acid bypass for
17 hours and the supernatant was collected to assay the total
amount of viral protein in the released virus particles. M1 was
chosen due to its abundance in the virus to maximize signal.
Nunc 96 well plates (eBoscience, 44-2404-21) were incubated
with capture antibody (Goat anti-M1, Abcam, 1:1000 diluted in
0.2 M sodium carbonate/bicarbonate buffer, pH 9.4) at room
temperature for 2 hours. After three 5 minutes wash with PBST
(0.05% Tween in PBS), the plates were blocked with PBSA (2%
BSA in PBST) for 1 hour. The supernatant was mixed with RIPA
buffer (1:2 dilution), and added in each well for overnight
incubation at 4uC. The samples were washed three times with
PBST, and incubated with detection antibody (Mouse anti-M1,
AbD Serotec, 1:600 dilution in PBSA) for 1 hour at room
temperature, washed three times, and further incubated with
HRP-conjugated goat anti-Mouse antibody (Bio-Rad, 172-1011,
1:5,000) for 1 hour. TMB substrate (Thermo Scientific, N301)
was used to detect HRP activity, and the reaction was stopped by
0.18 M sulfuric acid before measuring the absorbance at 450 nm.
The experiment was performed with triplicate samples from
independent infections, with three measurements for each
sample. To confirm the efficiency of detection, purified X-31
virus (Charles River laboratory) was used as a standard sample
(data not shown).
Quantification of the number of released virions
Control and CD81 siRNA treated cells were infected with
influenza virus by acid bypass treatment. At 17 hours post
infection, supernatant was collected to assay for the number of
released virions through immunofluorescence. Briefly, the super-
natant was absorbed on poly-lysine coated Lab-Tek 8 well glass
dishes at 4uC overnight. After washing away unbound virions with
PBS twice, the sample was fixed with 4% PFA for 15 minutes,
blocked with 3% PBSA buffer, immunostained with anti-HA and
anti-M1 antibody, and then imaged by confocal microscopy. More
than 150 randomly selected regions were imaged, and the number
of particles positive for HA and M1 staining was quantified (with
more than 600 virus particles).
Single particle tracking
The single-particle tracking experiment has been described in
detail previously [5,41–43]. Briefly, A549 cells were nucleofected
with CD81-mEmerald or RFP-Rab5 plasmids 24 hours prior to
single virus tracking experiments. After washing the cells with pre-
warmed PBS twice, 2.66104 PFU/ml DiD-labeled X-31 virus
diluted in imaging buffer (9 parts DMEM without phenol red, 1
part pH 8 Hepes buffer, supplemented with oxygen scavenge
system: 0.8 mg/ml dihydroxybenzoic acid (PCA, Sigma, 37580),
0.5 U/ml protocatechuate 3,4- dioxygenase (PCD, Sigma, P8279))
was added to the cells. The objective and stage of the microscope
were heated to maintain the temperature at 37uC for the cells.
Image acquisition began immediately after adding DiD-labeled
virus in situ. To obtain a simultaneous imaging of DiD-labeled
virus and cellular protein, DiD was excited with a 647 nm krypton
laser (Coherent) while mEmerald and RFP was excited with a
488 nm argon ion laser (Coherent) and a 561 nm solid state laser
(CrystaLaser) respectively. Fluorescence emissions from DiD and
mEmerald/RFP were separated by a 630 nm long-pass dichroic,
filtered with bandpass filters (705/40 for 647 channel, 525/40 for
488 channel, and 605/70 for 561 channel) and imaged on a
EMCCD camera (Andor) with 0.5 second exposure time. The
imaging analysis was performed as described previously [5].
Briefly, for each image, the fluorescence signal collected from the
DiD channel was convolved with a Gaussian spatial filter to
remove background and noise. To identify the virus peaks, the
algorithm performs recursive integration over bright regions
connected to each local maximum. The centroid of each
fluorescent peak was computed to determine the virus particle
position, and the trajectories were obtained by reconstructing
paired peaks between adjacent frames with similar proximity and
intensity. The fluorescence intensity of DiD was plotted versus
time.
Bulk viral fusion assay
Control or CD81-knockdown A549 cells seeded in Lab-Tek 8
well glass dishes were rinsed with cold PBS first, and then
incubated with 26104 PFU/ml DiD-labeled X-31 diluted in
DMEM (without serum) for 45 minutes at 4uC. After washing
away unbound viruses with cold PBS twice, pre-warmed full
culture medium was added in and cells were maintained at 37uC
for indicated amounts of time. At the end of each time point, cells
were trypsinized and immediately fixed with 2% PFA for
20 minutes. Afterwards, cells were washed and resuspended with
PBS. DiD-fluorescent intensity was measured through a flow
cytometer. At least 10,000 cells were measured for each
measurement with duplicates for each condition. The data was
analyzed with FlowJo. The normalized viral fusion extent (mean
DiD intensity at each time point-initial mean DiD intensity)/Initial
mean DiD intensity) was plotted.
STORM
STORM experiments were performed as previously described
on an Olympus IX71 inverted optical microscope [65]. Three
lasers were used in this study for STORM: 657 nm (RCL-300-
656; Crystalaser), 488 nm (Sapphire 460-10; Coherent) and
405 nm (CUBE 405-50C; Coherent). A high-numerical-aperture
(NA) oil-immersion objective (1006UPlanSapo, NA1.4; Olympus)
was used to collect the fluorescence emission, which is imaged onto
a back-illuminated electron-multiplying charge-coupled device
(EMCCD) camera (iXON DU-897; Andor). For two-color 3D
imaging of Alexa Fluor 647 and Atto 488, two imaging laser
beams (488 nm and 657 nm) and an activation laser beam
(405 nm) were reflected by a custom-designed polychroic mirror
(z488/647/780rpc; Chroma). Fluorescence emission from Alexa
Fluor 647 and Atto 488 were separated by a 630 nm long-pass
dichroic mounted on a commercial beamsplitting device (3D
Dual-View with a cylindrical lens, 100 cm focal length; Photo-
metrics). Two bandpass filters: FF01-535/50(Semrock) and
ET705/72m (Chroma) were used to filter for the short-wavelength
and long-wavelength channel independently. In addition to the
bandpass filters, a double-notch filter (NF01-488/647; Semrock)
was added before the Dual-View (Photometrics) to block the two
excitation laser beams. STORM imaging for each channel was
performed at 60 Hz sequentially and each channel was imaged
onto 2566256 pixels in the EMCCD camera (iXON DU-897).
STORM images were generated using similar methods as
previously described [65]. The STORM images in the Alexa
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Fluor 647 and Atto 488 channels were aligned by a third-order
polynomial warping map in three dimensions obtained from
calibration images of 100-nm Tetraspeck fluorescent beads. The
residual alignment error was ,7 nm in x-y and ,20 nm in z
dimensions. To correct for the sample drift during imaging
acquisition, we relied on the correlation function of imaging itself
to correct for the lateral and axial drift, as previously described
[48]. Since the imaging acquisition was performed sequentially
with the longer wavelength channel first, 647 channel was drift-
corrected to the last frame of the 647 nm acquisition while 488
channel was drift-corrected to the first frame of the 488 nm
acquisition. The spatial resolution measured was 20,30 nm
laterally and 50,60 nm axially for Alexa Fluor 647; while Atto
488 gives a lateral resolution of 30,40 nm and axial resolution of
,100 nm.
Electron microscopy
A549 cells were infected with influenza viruses at a MOI of 2.
Infection was allowed to proceed for a total of 15 hours before
fixing with 2.5% PFA/GA in 0.1M sodium cacodylate buffer,
pH 7.4 (Electron Microscopy Sciences, 15949) at room temper-
ature for at least 1 hour. The cells were post-fixed for 30 minutes
in 1% Osmium tetroxide (OsO4)/1.5% potassium ferrocyanide
(KFeCN6), washed in water three times and incubated in 1%
aqueous uranyl acetate for 30 minutes followed by two washes in
water and subsequent dehydration in grades of alcohol (5 minutes
each; 50%, 70%, 95%, 26100%). Cells were removed from the
dish in propyleneoxide, pelleted at 3000 rpm for 3 minutes and
infiltrated for 2 hours in a 1:1 mixture of propyleneoxide and
TAAB Epon (Marivac Canada Inc. St. Laurent, Canada). The
samples subsequently embedded in TAAB Epon and polymerized
at 60uC for 48 hours. Ultrathin sections (about 60 nm) were cut on
a Reichert Ultracut-S microtome, transferred onto copper grids
stained with lead citrate and examined in a TecnaiG2 Spirit
BioTWIN and images were recorded with an AMT 2k CCD
camera.
For immunogold electron microscopy, at the end of indicated
time points of virus infection, cells were rinsed with PBS once,
fixed with 4% PFA for 15 minutes, and blocked with PBSA (3%
BSA in PBS) for 30 minutes. Primary antibodies diluted in PBSA
(1:500) were incubated with cells for overnight at 4uC. After three
washes with PBS, cells were treated with 6 nm gold-conjugated
secondary antibodies (1:40) for four hours, post-fixed with 2.5%
PFA/GA in 0.1 M sodium cacodylate buffer for at least one hour.
The sample were embedded and sectioned as described above for
transmission electron microscope imaging.
Supporting Information
Figure S1 CD81 depletion efficiency with different
siRNA constructs. A) Six different siRNA constructs were
tested for CD81-knockdown efficiency after 48 hours of electro-
poration. CD81 expression was measured by flow cytometry
following staining with anti-CD81 primary antibody and fluores-
cently labeled secondary antibody. At least 10,000 cells were
measured for each condition. The orange, blue and magenta
curves correspond to the intensity profiles measured for cells
without addition of the primary antibody, control (non-targeting)
siRNA treated cells immunostained for CD81, and CD81 siRNA
treated cells immunostained for CD81, respectively. B) Quantita-
tive summary of the measurements from (A). CD81 siRNA 1 was
selected for subsequent studies. C) A549 cells were treated with
control or CD81 siRNA 1 for 48 hours. Cells were either
permeabilized with detergent or not permeabilized to detect the
total amount of CD81 in cells or the amount of CD81 on the cell
surface, respectively. The intracellular CD81 level was then
calculated by subtracting the amount of CD81 on the cell surface
from the total amount of CD81. Based on the quantification, the
cell-surface and intracellular CD81 fractions were ,92% and 8%
in control cells, respectively. The partition is similar in CD81-
knockdown cells (87% versus 13% for cell-surface and intracellular
CD81, respectively). A two-tailed t-test was performed in each case
and the p values were provided. D) CD81 knockdown does not
affect the expression of CD81-associating proteins. A549 cells were
treated with control or CD81 siRNA for 48 hours. Cells were
harvested for western blotting with indicated antibodies. Actin and
tubulin were used as loading controls.
(EPS)
Figure S2 The CD81-mEmerald expression does not
affect CD81 distribution or influenza viral fusion and
infection. A) A549 cells were nucleofected with CD81-
mEmerald plasmid for 24 hours, and subsequently immuno-
stained with anti-CD81 antibody. Note that there is an almost
complete overlap between CD81-mEmerald signal and CD81
antibody staining. B) CD81 partially colocalizes with early
endosomes marker. A549 cells were nucleofected with CD81-
mEmerald plasmid for 24 hours, and subsequently immuno-
stained with anti-EEA1 antibody. C) A549 cells were immuno-
stained with anti-CD81 and anti-EEA1 antibody to show the
partial colocalization between endogenous CD81 and EEA1. D)
Quantification of colocalization between CD81 and EEA1. We
randomly selected 2500,3000 CD81+ vesicles from confocal
slices, and quantified the colocalization between CD81-mEmer-
ald or endogenous CD81 and EEA1. For the CD81-mEmerald
expressing cells, about 37611% of the CD81-mEmerald+ vesicles
were positive for EEA1 and about 33612% of the EEA1+
vesicles were positive for CD81-mEmerald. A similar colocaliza-
tion level was observed for endogenous CD81 and EEA1 in
untransfected cells: about 34613% of the CD81+ vesicles were
positive for EEA1 and about 38614% of the EEA1+ vesicles
were positive for CD81. E) CD81-mEmerald expression does not
affect influenza viral fusion. A549 cells were nucleofected with
CD81-mEmerald or control GFP plasmid for 24 hours. Bulk viral
fusion assay was performed at indicated times. The error bar was
standard deviation from triplicates. F) CD81-mEmerald expres-
sion does not affect influenza infection. A549 cells were
nucleofected with CD81-mEmerald or control GFP plasmid for
24 hours. Cells were infected with X-31 or WSN with a
MOI,0.1 for 36 hours. The virus titer in the supernatant was
measured by plaque assays. The error bar was standard deviation
from triplicates.
(EPS)
Figure S3 Fusion of influenza viruses primarily occurs
in Rab5-positive endosomes in both control and CD81-
knockdown cells. A) An influenza virus particle enters and fuses
within a Rab5-positive endosome after entry. Live-cell confocal
imaging of DiD-labeled X-31 added in situ to RFP-Rab5
expressing A549 cells maintained at 37uC. The images were
collected with a 0.5 s interval. A-1) Several snapshots taken at
different time points with the virus indicated by the white circles.
A-2) The fluorescence signal of the indicated DiD-labeled virus as
a function of time. Note that viral fusion event occurred at 434 s.
B) Influenza virus occasionally fuses in a Rab5-negative endosome.
B-1) Several snapshots taken at different time points with the virus
indicated by the white circles. B-2) The fluorescence signal of the
indicated DiD labeled virus as a function of time. Viral fusion
event occurred at 85 s. C) C-1) Among 40 virus particles that fused
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in control cells, 8664% enter and fuse within Rab5+ endosomes,
whereas the remaining fuse in Rab5- endosomes. C-2) Among 35
virus particles that fused in CD81-knockdown cells, 8963% enter
and fuse within Rab5+ endosomes, whereas the remaining fuse in
Rab5- endosomes. The error is the standard deviation from two
independent experiments. D) Virus fusion in RFP-Rab5 express-
ing cells is impaired upon CD81 depletion. Experiments were
performed similarly as in Figure 3F except that cells were
nucleofected with RFP-Rab5 plasmids. Only those cells expressing
RFP-Rab5 were selected for flow cytometry analysis. Error bars
are standard deviation from triplicate measurements. A two-tailed
t-test was performed and the p value is provided.
(EPS)
Figure S4 Colocalization between CD81 and various
viral proteins at the virus budding sites. A) Cells were
infected with X-31 for 16 hours, fixed, permeabilized and
immunostained with anti-NA (red) and anti-CD81 (green). Scale
bar: 10 mm. B) Cells were infected with X-31 for 16 hours, fixed
and immunostained with anti-M2 (red) and anti-CD81 (green)
without permeabilization. Scale bar: 10 mm. C) Cells were infected
with Udorn for 16 hours, fixed, permeabilized and immuno-
stained with anti-HA (red) and anti-PB1 (green). Scale bar: 10 mm.
D) Cells were infected with Udorn for 16 hours, fixed, permea-
bilized and immunostained with anti-M2 (red) and anti-PB1
(green). Scale bar: 10 mm. E) Cells were infected with Udorn for
16 hours, fixed, permeabilized and immunostained with anti-NA
(red) and anti-CD81 (green). Scale bar: 10 mm. F) Cells were
infected with Udorn for 16 hours, fixed, permeabilized and
immunostained with anti-HA (red) and anti-CD81 (green). Scale
bar: 10 mm. G) Cells were infected with Udorn for 16 hours, fixed,
permeabilized and immunostained with anti-Udorn serum (red)
and anti-CD81 (green). Scale bar: 10 mm. H) CD81-knockdown
cells were infected with Udorn for 16 hours, fixed, permeabilized
and immunostained with anti-Udorn serum (red) and anti-CD81
(green). Scale bar: 10 mm.
(EPS)
Figure S5 CD81 expression level is decreased modestly
with influenza virus infection. A) The amount of CD81
expression in uninfected or X-31 infected cells was assayed
through flow cytometry. A549 cells were immunostained with NP
and CD81. Cells were gated based on their NP intensity for
further analysis of CD81 expression level. On the left panel, the
black, red and blue curves correspond to the NP intensity profiles
measured for cells without adding the primary antibody against
NP, cells not infected with influenza virus and cells infected with
influenza virus, respectively. Specifically, NP- cells that correspond
to cells in the orange band in the left panel were selected for
analyzing CD81 intensity in uninfected cells, while NP+ cells that
correspond to cells in the blue band in the left panel were selected
for analyzing CD81 intensity in X-31 infected cells. The
fluorescence intensity of CD81 is plotted on the right panel,
where the black, red and blue curves correspond to the CD81
intensity profiles measured for cells without adding the primary
antibody against CD81, NP- cells and NP+ cells, respectively. At
least 10, 000 cells were quantified in each condition. B)
Quantification of CD81 expression level in cells with or without
X-31 infection based on the analysis described in (A). The cells
were infected by X-31 for 17 hours. Note that there is about 20%
decrease in CD81 expression with X-31 infection. The error bars
are the standard deviation from duplicate measurements.
(EPS)
Figure S6 CD81 is enriched in the budding WSN virions
and CD81-knockdown impairs scission of the X-31
virus. A) CD81 is incorporated in budding WSN viruses. Cells
were infected with WSN for 15 hours, and CD81 was immuno-
gold labeled for electron microscopy. An enlarged image of the
area in the white box is shown on the upper right. Scale bar:
100 nm. B) EM image of budding X-31 virus in control cells. A549
cells were infected with X-31 virus with the acid-bypass treatment
for 16 hours. Scale bar: 200 nm. C) Budding X-31 viruses in
CD81-knockdown cells. A549 cells were infected with X-31 virus
with the acid-bypass treatment for 16 hours. Note that a
substantial fraction of budding viruses have their open membrane
neck connected to the plasma membrane (arrowheads). Scale bar:
200 nm.
(EPS)
Figure S7 HA alone can recruit CD81 into HA-enriched
clusters. A) A549 cells were electroporated with pCAGGS-HA/
Udorn plasmids for 24 hours and immunostained with HA (red)
and CD81 (green) antibodies. HA (red) was probed with Alexa
Fluor 647 labeled anti-HA and CD81 (green) was probed with
FITC conjugated anti-CD81. Images are XY cross-sections from
confocal images. Scale bar: 10 mm. B) Experiments were
performed similarly as in (A) except the cells were mock
transfected with a vector plasmid. Images are XY cross-sections
from confocal images. Scale bar: 10 mm. C) A549 cells were
electroporated with pCAGGS-NA/Ud plasmid for 24 hours, fixed
and immunostained with anti-CD81 (green) and anti-NA (red)
antibodies. NA (red) was probed with Alexa Fluor 647 labeled
anti-NA and CD81 (green) was probed with FITC conjugated
anti-CD81. Scale bar: 10 mm. D) Experiments were performed
similarly as in (C) except the cells were mock transfected with a
vector plasmid. Scale bar: 10 mm.
(EPS)
Movie S1 An influenza virus particle enters and fuses
within a CD81-positive endosome after entry. Live cell
confocal imaging of DiD-labeled X-31 added in situ to CD81-
mEmearld expressing A549 cells maintained at 37uC. The images
were collected with a 0.5 s interval. Movie is played seven times
faster than the raw acquired data.
(WMV)
Movie S2 An influenza virus particle fuses in a CD81-
negative endosome. Live cell confocal imaging of DiD-labeled
X-31 added in situ to CD81-mEmearld expressing A549 cells
maintained at 37uC. The images were collected with a 0.5 s
interval. Movie is played seven times faster than the raw acquired
data.
(WMV)
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